Republica Cehă - cehă - SUKL (Státní ústav pro kontrolu léčiv)

sandoz s.r.o., praha array - 16808 monohydrÁt takrolimu - tvrdá tobolka s prodlouženým uvolňováním - 5mg - takrolimus

Republica Cehă - cehă - SUKL (Státní ústav pro kontrolu léčiv)

astellas pharma s.r.o., praha array - 16808 monohydrÁt takrolimu - tvrdá tobolka - 0,5mg - takrolimus

Republica Cehă - cehă - SUKL (Státní ústav pro kontrolu léčiv)

astellas pharma s.r.o., praha array - 16808 monohydrÁt takrolimu - tvrdá tobolka - 1mg - takrolimus

Republica Cehă - cehă - SUKL (Státní ústav pro kontrolu léčiv)

astellas pharma s.r.o., praha array - 16808 monohydrÁt takrolimu - tvrdá tobolka - 5mg - takrolimus

Republica Cehă - cehă - SUKL (Státní ústav pro kontrolu léčiv)

astellas pharma s.r.o., praha array - 12314 takrolimus - koncentrát pro infuzní roztok - 5mg/ml - takrolimus

Uniunea Europeană - cehă - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - karcinom, plicní jiná než malobuněčná - jiná cytostatika, inhibitory proteinkinázy - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Republica Cehă - cehă - SUKL (Státní ústav pro kontrolu léčiv)

pro.med.cs praha a.s. array - 9219 itrakonazol - tvrdá tobolka - 100mg - itrakonazol

Uniunea Europeană - cehă - EMA (European Medicines Agency)

idorsia pharmaceuticals deutschland gmbh - daridorexant hydrochloride - poruchy spánku a poruchy při údržbě - psycholeptika - quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.

Uniunea Europeană - cehă - EMA (European Medicines Agency)

bayer ag - riociguat - hypertenze, plicní - antihypertenzíva pro plicní arteriální hypertenzi - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. Účinnost byla prokázána v pau populace, včetně etiologie idiopatické nebo dědičné pah nebo pah spojenou s onemocněním pojivové tkáně. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.

Republica Cehă - cehă - SUKL (Státní ústav pro kontrolu léčiv)

litcon pharma se, praha 8 array - 9219 itrakonazol - tvrdá tobolka - 100mg - itrakonazol